ArticleJAMA network open2024

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.

Christina M Zettler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.